Korean J Pediatr Gastroenterol Nutr.  2010 Mar;13(1):44-50. 10.5223/kjpgn.2010.13.1.44.

Experience with Entecavir Therapy for Lamivudine-Resistant Chronic Hepatitis B in Korean Children and Adolescents

• Cho SM
• Choe BH
• Chu MA
• Kim JM

• KMID: 1459443
• DOI: http://doi.org/10.5223/kjpgn.2010.13.1.44

Abstract

PURPOSE
To estimate the viral suppressive effect of entecavir monotherapy in Korean children and adolescents with lamivudine-resistant chronic hepatitis B (CHB).
METHODS
One milligram of entecavir was administered once daily to 6 patients (4 boys; mean age, 17.5 years; range, 15.10~24.6 years) with lamivudine-resistant CHB for a mean duration of therapy of 13.4 months (range, 1~21.1 months). The therapeutic results were compared with 11 patients who received adefovir (0.3 mg/kg/day [maximal dose 10 mg]) for at least 12 months (mean, 33.4 months; range, 12.4~58.3 months). The serum HBV DNA level and serologic markers were measured every 2 months.
RESULTS
The interval to a HBV DNA titer decrement (>1 log(10)) was 1.2+/-0.2 and 4.4+/-5.2 months (p=0.185) for the entecavir and adefovir groups, respectively. The interval to a HBV DNA titer decrement (>2 log(10)) was 2.4+/-2.3 and 9.2+/-7.3 months (p=0.025), for the entecavir and adefovir groups, respectively.
CONCLUSION
The therapeutic efficacy of entecavir was favorable in children and adolescents, especially in shortening the interval to a >2 log(10) decrement in the HBV DNA titer. Long-term follow up is needed to determine the therapeutic efficacy of entecavir for lamivudine-resistant CHB in children and adolescents.

Keyword

Entecavir; Adefovir; Lamivudine; Chronic hepatitis B; Resistance

MeSH Terms

Adenine
Adolescent
Child
DNA
Follow-Up Studies
Guanine
Hepatitis B, Chronic
Hepatitis, Chronic
Humans
Lamivudine
Organophosphonates
Adenine
DNA
Guanine
Lamivudine
Organophosphonates